Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...

Dyno Therapeutics unveils best-in-class Dyno-bn8 AAV vector for muscle gene therapies, achieving therapeutic delivery with improved safety potential ...

MUNICH & COPENHAGEN, Denmark--(BUSINESS WIRE)--SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, and InProTher Aps (“InProTher” ...

Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

WEST PALM BEACH, FL, Sept. 22, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTCID: FOXO) (“FOXO” or the “Company”), announces the closing of the acquisition of Vector Biosource Inc. (“Vector”).

FOXO Technologies Inc. announced a non-binding agreement to acquire Vector Biosource Inc., a provider of biospecimen sourcing in the biotech and pharmaceutical sectors, with expected revenue of ...

MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell ...